Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Analysis of no bolus versus bolus unfractionated heparin nomograms in the management of pulmonary embolism: Insights from a real-world cohort

Jia Qi Xiong, David Von Nordheim, Maame Dei et al. Nov 03, 2025 pp. 3117-3117 10.1182/blood-2025-3117

Abstract Background: Unfractionated heparin (UFH) is a cornerstone of acute pulmonary embolism (PE) management. A weight-based UFH nomogram,...

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Ayo Falade, Raphael Mwangi, Izel Okcu et al. Nov 03, 2025 pp. 473-473 10.1182/blood-2025-473

Abstract Background Secondary central nervous system lymphoma (SCNSL) is a rare but significant complication, affecting...

Trial in progress: nutrition and exercise to optimize muscle and adiposity in adolescents and young adults with B-cell acute lymphocytic leukemia: The neoma ALL trial

Samuel Yates, Lauren Miller, Suzanne Massarani et al. Nov 03, 2025 pp. 1581-1581 10.1182/blood-2025-1581

Abstract Background and Significance: In 2021-2023, 40% of adults in the United States were obese (Emmerich, NCHS Data B...

Decoding acquired platelet dysfunction with eosinophilia: Clinical triad and flow cytometric signatures

Anusha Thangaraja, Tulasi Geevar, Nitty Mathews et al. Nov 03, 2025 pp. 4809-4809 10.1182/blood-2025-4809

Abstract Background Acquired Platelet Dysfunction with Eosinophilia (APDE) is a rare, under-recognized bleeding disorder...

Cardiovascular adverse events associated with bispecific antibodies in Relapsed/Refractory hematologic malignancies: A comprehensive systematic review and meta-analysis

Harshawardhan Dhanraj Ramteke, Aman Narula, Sravani Bhavanam et al. Nov 03, 2025 pp. 8091-8091 10.1182/blood-2025-8091

Abstract Introduction: Bispecific antibodies (BsAbs), targeting two distinct antigens, offer promising treatment for relapsed/refractory hem...

Transcriptomic characterization of platelets in immune thrombocytopenia indicates sustained activation and mitochondrial dysfunction

Julia-Annabell Georgi, Marita Hartwig, Ulrike Anne Friedrich et al. Nov 03, 2025 pp. 1239-1239 10.1182/blood-2025-1239

Abstract Background Immune Thrombocytopenia (ITP) is a rare hematologic autoimmune disease marked by platelet (PLT) destruction and impaired...

The rearrangement partner and the presence of MYC mutations determines outcome of patients with MYC and BCL6 rearrangements

Anna Stengel, Miriam Lenk, Wolfgang Kern et al. Nov 03, 2025 pp. 1749-1749 10.1182/blood-2025-1749

Abstract Background: MYC and BCL6 rearrangements (r) in high-grade B-cell lymphoma (HGBL) are generally associated with aggressive disease a...

The impact of duffy-null phenotype on neutrophil counts in patients with HbSC/ HbSβ+-thalassemia treated with hydroxyurea

Yan Zheng, Jeffrey Gossett, Matthew Wogksch et al. Nov 03, 2025 pp. 1182-1182 10.1182/blood-2025-1182

Abstract Introduction: The Duffy-null phenotype is characterized by the lack of Duffy antigen expression on red cells and is associated with...

ST2 promotes leukemia transformation by reshaping the immune landscape in Acute Myeloid Leukemia

Yu-Hsuan Fu, Man Li, Ying-Chieh Chen et al. Nov 03, 2025 pp. 1459-1459 10.1182/blood-2025-1459

Abstract Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a 5-year survival rate of 30%, largely due to treatment...

A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress

Paul Saultier, Suthesh Sivapalaratnam, Frederico Xavier et al. Nov 03, 2025 pp. 8232-8232 10.1182/blood-2025-8232

Abstract Background: Glanzmann thrombasthenia (GT) is a severe genetic bleeding disorder characterized by impaired platelet aggregation prev...

Deciphering clonal progression in MDS via longitudinal sequencing

Asmita Shukla, Jeff Justin Aguilar, Vikramjit Dhillon et al. Nov 03, 2025 pp. 2066-2066 10.1182/blood-2025-2066

Abstract Introduction Next-generation sequencing (NGS) has redefined the molecular taxonomy of myelodysplastic syndromes...

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Meghan Thompson, Anthony Mato, Lia Palomba et al. Nov 03, 2025 pp. 5676-5676 10.1182/blood-2025-5676

Abstract Background: Advantages of covalent Bruton Tyrosine Kinase inhibitor (cBTKi) treatment (tx), as compared to BCL2 inhibitor (BCL2i) c...

A Phase 1b/ 2a study of budoprutug in patients with immune thrombocytopenia (ITP)

Jay Mitchell, Jan Hillson, Viktoriia Bilenko et al. Nov 03, 2025 pp. 1274-1274 10.1182/blood-2025-1274

Abstract Background and Significance: Immune thrombocytopenia (ITP) is a rare disorder caused by accelerated, premature platelet destruction...

HLA alleles associated with inhibitor development in severe hemophilia A: Analysis of the “My life, our Future” hemophilia A cohort

Sara Contente, Anwar Ahmed, Barbara Konkle et al. Nov 03, 2025 pp. 1294-1294 10.1182/blood-2025-1294

Abstract An earlier analysis of data from the “My Life, Our Future” (MLOF) Research Repository (Ahmed and Pratt, 2023, PMID 36696179) indica...

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Lori Muffly, Edward Abadir, Mark Geyer et al. Nov 03, 2025 pp. 5954-5954 10.1182/blood-2025-5954

Abstract Background and significance Relapsed/Refractory (R/R) T-ALL/LBL remains a significant therapeutic challenge due to lack of effectiv...

Cumulative cardiac risk strongly predicts in-hospital mortality and cost burden in patients hospitalized with chronic lymphocytic leukemia: A national inpatient analysis, 2020–2022

Canan Dirican, Anas Al Mardini, Amara Sofia et al. Nov 03, 2025 pp. 4414-4414 10.1182/blood-2025-4414

Abstract Background: Chronic lymphocytic leukemia (CLL) primarily affects older adults who often have preexisting cardiovascular comorbiditi...

Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study

Akshay Ratnani, Thitiphan Srikulmontri, Riley Marotta et al. Nov 03, 2025 pp. 8136-8136 10.1182/blood-2025-8136

Abstract Background Clinical depression is associated with immune dysregulation and reduced activity of natural killer c...

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

David Kuter, Nicola Cooper, Mattea Orsini et al. Nov 03, 2025 pp. 1105-1105 10.1182/blood-2025-1105

Abstract Background: Warm autoimmune hemolytic anemia (wAIHA) is characterized by complex immune dysregulation along with red blood cell des...

Characterization of sickle cell disease-associated organ dysfunction in aged Townes HbSS mice and effect of IMA001

Marielle Margier, Giulia Scorrano, Cecile Cros et al. Nov 03, 2025 pp. 2929-2929 10.1182/blood-2025-2929

Abstract Introduction: Sickle cell disease (SCD) is a hemolytic anemia caused by a mutation in the β-globin gene. Recurrent vaso-occlusive c...

Evolutionarily divergent notch regulation underpins the initiation of human T-cell development

Vinothkumar Rajan, Christina Lee, Juan Carlos Zúñiga-Pflücker Nov 03, 2025 pp. 1231-1231 10.1182/blood-2025-1231

Abstract Hematopoietic stem and progenitor cells (HSPCs) differentiate into diverse blood cell lineages through intricate genetic and epigen...

Allogeneic hematopoietic stem cell transplantation outcomes in pediatric acute lymphoblastic leukemia: A multicenter analysis from the cccg-ALL-2015 protocol

Xiaohang Huang, Ruijuan Sun, Jiaoyang Cai et al. Nov 03, 2025 pp. 6074-6074 10.1182/blood-2025-6074

Abstract Background Acute lymphoblastic leukemia (ALL) represents the most prevalent pediatric malignancy. The Chinese C...

The efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitor AND017 in NUP98-HOXD13transgenic mouse

Fuhui Li, Jinqin Liu, Lin Yang et al. Nov 03, 2025 pp. 3273-3273 10.1182/blood-2025-3273

Abstract Introduction Most of patients with myelodysplastic syndromes/neoplasms (MDS) exhibit variable degrees of anemia at diagnosis, primar...

Hibiscus 2 (Trial-in-Progress): A global, Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease

Guanglin Wu, Pavithra Dhayakar Nov 03, 2025 pp. 2976-2976 10.1182/blood-2025-2976

Abstract Background and Significance: Pyruvate kinase red blood cell (RBC) isozyme (PKR) is a key enzyme in glycolysis....

Facility-level disparities in outcomes of subcutaneous panniculitis-like T-cell lymphoma: A national cancer database analysis

Gabriel Giraldo Ospino, Leyla Bojanini, Erin Kaser et al. Nov 03, 2025 pp. 8023-8023 10.1182/blood-2025-8023

Abstract Background Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an exceptionally rare malignancy, representing less than 1% of...

Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran)

Sibgha Zaheer, Elizabeth Marquez Casas, Shariq Ali et al. Nov 03, 2025 pp. 4849-4849 10.1182/blood-2025-4849

Abstract Introduction: There are several assays for measuring antithrombin (AT) activity that each use different reagents, targeting human o...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page